Results 21 to 30 of about 13,526 (188)

Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy

BMC Pulmonary Medicine, 2019
Background Nintedanib is an inhibitor of receptor tyrosine kinases, including vascular endothelial growth factor receptor, but its effects on pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF) patients with chronic hypoxia were unclear ...
Masahiro Tahara, Keishi Oda, Kei Yamasaki, Takako Kawaguchi, Konomi Sennari, Shingo Noguchi, Noriho Sakamoto, Toshinori Kawanami, Hiroshi Mukae, Kazuhiro Yatera   +9 more
doaj   +1 more source

Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis

BMC Pulmonary Medicine, 2019
Background Current clinical practice guidelines for idiopathic pulmonary fibrosis (IPF) conditionally recommend use of pirfenidone and nintedanib. However, an optimal treatment sequence has not been established, and the data of treatment sequence from ...
Satoshi Ikeda, Akimasa Sekine, Tomohisa Baba, Takuma Katano, Erina Tabata, Ryota Shintani, Shinko Sadoyama, Hideaki Yamakawa, Tsuneyuki Oda, Ryo Okuda, Hideya Kitamura, Tae Iwasawa, Tamiko Takemura, Takashi Ogura   +13 more
doaj   +1 more source

Nintedanib treatment.

, 2022
Nintedanib treatment.
Yumi Yoshikawa (5461178), Takashi Ichiyama (12042183), Hiroshi Yamamoto (28534), Masanori Yasuo (289536), Takeshi Uehara (6890225), Satoshi Kawakami (566529), Masayuki Hanaoka (295616), Yoshiaki Kitaguchi (320648), Masamichi Komatsu (12042180), Atsuhito Ushiki (12042186)   +9 more
core   +1 more source

Nintedanib in children and adolescents with fibrosing interstitial lung diseases [PDF]

, 2022
Childhood interstitial lung disease comprises a spectrum of rare ILDs affecting infants, children and adolescents. Nintedanib is a licensed treatment for pulmonary fibrosis in adults.
Cunningham, Steven, Dumistracel, Mihaela, Brown, Kevin K., Flaherty, Kevin R, Bertulis, Julia, Erhardt, Elvira, Stowasser, Susanne, Gahlemann, Martina, Cunningham, Steven; id_orcid, Deterding, Robin, Young, Lisa R, Griese, Matthias, ?, ?, Brown, Kevin K, Deboer, Emily M, DeBoer, Emily M., Young, Lisa R., Flaherty, Kevin R., Warburton, David, Schwerk, Nicolaus   +19 more
core   +1 more source

Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting

Drug Design, Development and Therapy, 2021
Motoyasu Kato,1 Shinichi Sasaki,1,2 Misa Tateyama,1 Yuta Arai,1 Hiroaki Motomura,1 Issei Sumiyoshi,1 Yusuke Ochi,1 Junko Watanabe,1 Hiroaki Ihara,1 Shinsaku Togo,1 Kazuhisa Takahashi1 1Department of Respiratory Medicine, Juntendo University Graduate ...
Kato M, Sasaki S, Tateyama M, Arai Y, Motomura H, Sumiyoshi I, Ochi Y, Watanabe J, Ihara H, Togo S, Takahashi K   +10 more
doaj  

Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib

Respirology Case Reports, 2020
Nintedanib, a tyrosine kinase inhibitor, is approved for the treatment of idiopathic pulmonary fibrosis. We report a case of left ventricular dysfunction in a patient with idiopathic pulmonary fibrosis treated with nintedanib, which recovered after ...
Ryosuke Imai, Yutaka Tomishima
doaj   +1 more source

Severe hepatotoxicity secondary to nintedanib.

, 2022
Nintedanib is a multikinase inhibitor used for the treatment of pulmonary idiopathic fibrosis.
Heredia Carrasco, Clara, Fernández Cano, María Del Carmen, Librero Jiménez, Marta   +2 more
core   +1 more source

Pirfenidone vs nintedanib for treatment of idiopathic pulmonary fibrosis in clinical practice: efficacy, tolerability, and adverse effects

Egyptian Journal of Chest Disease and Tuberculosis, 2020
Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal disease, with a median survival of ∼2–5 years. The main target of treatment was to stabilize or reduce the rate of disease progression. Nintedanib and pirfenidone are new
Amal A.E.-A Sadon, Ahmed S Kenawy, Ashraf H Abdelsalam, Hosam M Attia   +3 more
doaj   +1 more source

Adverse events of nintedanib treatment.

, 2022
Adverse events of nintedanib treatment.
Yumi Yoshikawa (5461178), Takashi Ichiyama (12042183), Hiroshi Yamamoto (28534), Masanori Yasuo (289536), Takeshi Uehara (6890225), Satoshi Kawakami (566529), Masayuki Hanaoka (295616), Yoshiaki Kitaguchi (320648), Masamichi Komatsu (12042180), Atsuhito Ushiki (12042186)   +9 more
core   +1 more source

Spontaneous pneumothorax during nintedanib therapy in patients with systemic sclerosis‐associated interstitial lung disease

Respirology Case Reports, 2021
Interstitial lung disease (ILD) is a common complication of systemic sclerosis (SSc). Nintedanib, an antifibrotic drug, has recently been approved for treating SSc‐ILD.
Toshiyuki Sumi, Hirofumi Uehara, Makoto Tada, Yoshiko Keira, Koki Kamada, Naoki Shijubou, Yuichi Yamada, Hisashi Nakata, Yuji Mori, Hirofumi Chiba   +9 more
doaj   +1 more source